Evidence map›Paper›PMID 34143284›Full record

ArticleWorld journal of urology2021

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer.

Satoshi Katayama, Keiichiro Mori, Benjamin Pradere, Ekaterina Laukhtina, Victor M Schuettfort, Fahad Quhal, Reza Sari Motlagh, Hadi Mostafaei, Nico C Grossmann, Pawel Rajwa and 10 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 9 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 9 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 12 countries.

Satoshi Katayama *Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0002-8377-2457
Keiichiro Mori *Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Benjamin PradereDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Ekaterina LaukhtinaDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Victor M SchuettfortDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Fahad QuhalDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Reza Sari MotlaghDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Hadi MostafaeiDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Nico C GrossmannDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Pawel RajwaDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Marco MoschiniDepartment of Urology, Luzerner Kantonsspital, Luzern, Switzerland.
Romain MathieuDepartment of Urology, Rennes University Hospital, 2 Rue Henri le Guilloux, 35000, Rennes, France.
Mohammad AbufarajDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
David D'AndreaDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Eva CompératDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Martin HaydterDepartment of Urology, Landesklinikum Wiener Neustadt, Vienna, Austria.
Shin EgawaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Yasutomo NasuDepartment of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.
European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)
Medical University of Vienna · ATJikei University School of Medicine · JPOkayama University · JPUniversity of Jordan · JOInstitut de Recherche en Santé, Environnement et Travail · FRInstitute Mutualiste Montsouris · FRKing Fahad Specialist Hospital · SAMedical University of Silesia · PLSechenov University · RUShahid Beheshti University of Medical Sciences · IRTabriz University of Medical Sciences · IRUniversität Hamburg · DEUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC)

methodsIn this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models.

resultsOverall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23-2.77; P = 0.003) and CSS (HR 2.53; 95% CI 1.42-4.48; P = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57-7.31; P = 0.002) and CSS (HR 4.93; 95% CI 1.70-14.3; P = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS.

conclusionPreoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.

Indexed as

AgedFemaleHumansInflammationMaleMiddle AgedNeoplasm InvasivenessPrognosisRetrospective StudiesRisk AssessmentUrinary Bladder NeoplasmsBiomarkerIntermediate-riskNMIBCSIISurvival

Identifiers

PMID34143284
PMCPMC8602174
OpenAlexW3167773209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.